Table 2.

Inclusion Criteria Applied to Patient Sample, for REGENRATE Clinical Trial

Inclusion Criteria	Inclusion met	Inclusion not met
Biopsy with all 3 features and NAS Score ≥ 4	142 (59.9%)	95 (40.1%)
Stage 2 or 3 fibrosis, or 1 with obesity, DM2, or ALT >1.5x ULN	138 (58.2%)	99 (41.8%)
Not on, or on stable dose TZD or vitamin E for 6 mo	234 (98.7%)	3 (1.3%)
Stable body weight (<10% variation for 3 mo)	224 (94.5%)	13 (5.5%)
Met all inclusion criteria	68 (28.7%)	169 (71.3%)

Acronyms: NAS, nonalcoholic fatty liver disease activity score